Published in Circulation on January 16, 2015
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con. Clin J Am Soc Nephrol (2016) 1.23
A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors. J Am Soc Nephrol (2016) 0.91
Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues. J Stroke (2016) 0.85
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vasc Health Risk Manag (2015) 0.78
Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol (2016) 0.78
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br J Clin Pharmacol (2016) 0.77
Reply: Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe? Nat Rev Nephrol (2015) 0.75
Anticoagulation in Atrial Fibrillation - Current Concepts. Arrhythm Electrophysiol Rev (2015) 0.75
Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart (2016) 0.75
Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1. Clin J Am Soc Nephrol (2016) 0.75
Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res (2016) 0.75
Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol (2017) 0.75
Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med (2017) 0.75
Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. Heart Vessels (2016) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost (2013) 1.83
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Can we rely on RE-LY? N Engl J Med (2009) 1.58
Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem (2002) 1.51
New options in anticoagulation for atrial fibrillation. N Engl J Med (2011) 0.97
Dabigatran and kidney disease: a bad combination. Clin J Am Soc Nephrol (2013) 0.95
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 0.81